Scientists Find Unexpected Immune Pathways for mRNA Cancer Vaccines Researchers at Washington University School of Medicine in St. Louis have discovered that mRNA vaccines against cancer can activate the immune system through an unconventional pathway, challenging previous assumptions about how these vaccines function. The findings, published April 15 in Nature, reveal that multiple types of dendritic cells contribute to anti-tumor immune responses, offering new insights for optimizing cancer vaccine design. MRNA vaccines work by delivering genetic instructions that teach cells to produce specific proteins found on cancer cells. The immune system then learns to recognize these proteins as threats and attacks cells bearing them. While this approach has shown promise in clinical trials for melanoma, lung cancer, and bladder cancer, scientists previously believed that one specific subtype of dendritic cell was essential for initiating the immune response. However, the new study in mice demonstrates that even without this presumed essential dendritic cell subtype, mRNA vaccines still trigger strong cancer-killing responses. Researchers found that a related dendritic cell subtype, previously not associated with vaccine responses, can also stimulate anti-tumor immunity. Mice lacking the originally assumed essential dendritic cells, as well as mice missing both dendritic cell subtypes, were still able to mount effective immune responses and reject tumor growth. “There is a lot of interest in applying the mRNA vaccine approaches used during the COVID-19 pandemic to the problem of inducing anti-tumor immunity,” said senior author Kenneth M. Murphy, MD, PhD, the Eugene Opie Centennial Professor of Pathology & Immunology at WashU Medicine. “By dissecting which immune cells are involved and how they coordinate the response, we’re offering vaccine developers some additional mechanistic insights to consider in their goal of optimizing these vaccines against tumor proteins.” Murphy, who is also a research member at Siteman Cancer Center based at Barnes-Jewish Hospital and WashU Medicine, emphasized that this unexpected flexibility in immune pathway utilization could aid scientists design more effective versions of cancer vaccines in the future. The discovery suggests that mRNA vaccine platforms may be more robust than previously thought, capable of engaging alternative immune routes when primary pathways are compromised. The research builds on the broader scientific effort to adapt mRNA technology—initially proven effective against SARS-CoV-2—for cancer treatment. Clinical trials are currently evaluating personalized mRNA vaccines for various cancers, including colorectal, pancreatic, and melanoma, through initiatives like the NHS Cancer Vaccine Launch Pad in collaboration with BioNTech. As scientists continue to unravel the complex interactions between mRNA vaccines and the immune system, these findings provide a foundation for developing more reliable and potent cancer immunotherapies. Understanding that multiple dendritic cell subtypes can contribute to tumor rejection may lead to vaccine formulations that work across a broader range of patient immune profiles.
28